{"id":"NCT00444951","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","officialTitle":"Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2008-02","completion":"2009-02","firstPosted":"2007-03-08","resultsPosted":"2011-03-04","lastUpdate":"2015-07-14"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Neisseria Meningitidis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine","otherNames":["Mencevax®"]},{"type":"BIOLOGICAL","name":"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine","otherNames":["Menactra®"]}],"arms":[{"label":"Menactra® group","type":"EXPERIMENTAL"},{"label":"Mencevax® group","type":"EXPERIMENTAL"},{"label":"Control group","type":"EXPERIMENTAL"}],"summary":"This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine. This study will evaluate the booster administration of Menactra® (Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine) compared with Mencevax® (Meningococcal A, C, Y, and W 135 Polysaccharide vaccine)in terms of their serum bactericidal antibody responses.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination","timeFrame":"Baseline (Day 0) and Day 28 after vaccination","effectByArm":[{"arm":"Menactra® Group","deltaMin":651.5,"sd":null},{"arm":"Mencevax® Group","deltaMin":889.7,"sd":null},{"arm":"Control Group","deltaMin":441.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":7,"countries":["Saudi Arabia"]},"refs":{"pmids":["25151042"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":144},"commonTop":["Injection site pain","Headache","Myalgia","Malaise","Injection site erythema"]}}